Skip to Content
Merck
CN

1430000

USP

Methylergonovine maleate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Methylergonovine maleate salt, 9,10-Didehydro-N-[(S)-1-(hydroxymethyl)propyl]-6-methylergoline-8β-carboxamide maleate salt, Methergine maleate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H25N3O2 · C4H4O4
CAS Number:
57432-61-8
Molecular Weight:
455.50
NACRES:
NA.24
PubChem Substance ID:
329750438
UNSPSC Code:
41116107
MDL number:
MFCD00078588

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

manufacturer/tradename

USP

InChI

1S/C20H25N3O2.C4H4O4/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13;5-3(6)1-2-4(7)8/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13-,14+,18-;/m1./s1

SMILES string

[H]\C(=C(/[H])C(O)=O)C(O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO)c34

InChI key

NOFOWWRHEPHDCY-DAUURJMHSA-N

grade

pharmaceutical primary standard

API family

methylergonovine

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... DRD1(1812), HTR2B(3357)

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Dopamine antagonist interacts with serotonergic, dopaminergic and α-adrenergic systems.
Ergot alkaloid which interacts with serotonergic, dopaminergic and α-adrenergic systems. Dopamine antagonist.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

flash_point_f

Not applicable

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Methylergometrine: adverse effects in breastfed infants.
Prescrire international, 23(148), 102-102 (2014-05-27)
[Reflections of an expert committee of the French Society of Cardiology on the use of methylergometrine maleate (Methergin) for the detection of abnormal coronary vasomotricity].
J M Lablanche et al.
Archives des maladies du coeur et des vaisseaux, 88(2), 247-253 (1995-02-01)
A J Butwick et al.
British journal of anaesthesia, 113(4), 661-668 (2014-06-08)
Uterine atony (UA) is recognized as a leading cause of postpartum haemorrhage. However, knowledge of risk factors of haemorrhage-related morbidity among patients diagnosed with UA is uncertain. We investigated risk factors for haemorrhage-related morbidity among patients undergoing Caesarean delivery with
Oral methylergonovine maleate for refractory migraine and cluster headache prevention.
Joel R Saper et al.
Headache, 53(2), 378-381 (2013-02-26)
L Mueller et al.
Headache, 37(7), 437-442 (1997-07-01)
Methylergonovine maleate (Methergine), an ergot derivative with vasoconstrictive properties, has been cited as an effective treatment for vascular headaches. Few studies are available to support its use in headache management. An uncontrolled pilot study of 20 episodic cluster headache patients

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service